TP53 and lymphoma: Most of them increased in abundance after N3a treatment except for three proteins: CCND1 (oncogene, accused to be involved in B-lymphocytic malignancy, particularly mantle-cell lymphoma -MCL), RNF20 (involved in the pathway protein ubiquitination), and PSME3 (facilitates the MDM2-TP53 interaction, which promotes ubiquitination and MDM2-dependent proteasomal degradation of TP53), indicating an activated TP53 signaling pathway in all three lymphoma cells.